Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) – Pipeline Review, H1 2018’, provides in depth analysis on Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Musculoskeletal Disorders, Cardiovascular, Toxicology, Central Nervous System, Infectious Disease and Respiratory under development targeting Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)

– The report reviews Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics and enlists all their major and minor projects

– The report assesses Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Paradigm Biopharmaceuticals Ltd

Pfizer Inc

Takeda Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC

3.4.24.) Overview

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC

3.4.24.) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC

3.4.24.) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC

3.4.24.) Companies Involved in Therapeutics Development

Paradigm Biopharmaceuticals Ltd

Pfizer Inc

Takeda Pharmaceutical Co Ltd

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC

3.4.24.) Drug Profiles

pentosan polysulfate sodium Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-152 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MMP-13 for Osteoarthritis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit MMP2,9 and 13 for Myocardial Infarction Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZF-198 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZF-760 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC

3.4.24.) Dormant Products

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC

3.4.24.) Discontinued Products

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC

3.4.24.) Product Development Milestones

Featured News & Press Releases

Mar 01, 2018: Paradigm Reports Osteoarthritis Pain Reduced by 50%

Jan 24, 2018: Current and past elite sportspeople successfully treated with PPS

Jan 16, 2018: European Patent Granted for Bone Marrow Edema Lesions

Nov 23, 2017: Paradigm’s Two Arthritis Phase 2 Clinical Trials on Schedule

Nov 14, 2017: Paradigm Reports Successful Phase 2a BML/ACL Clinical Trial Results

Oct 30, 2017: First Participant Successfully Dosed in Phase 2b Clinical Trial for Osteoarthritis

Sep 19, 2017: Ethics Approval Received for Phase 2b Clinical Trial for Osteoarthritis

Sep 14, 2017: Paradigm Biopharmaceuticals: Significant momentum with Phase 2 Ross River Virus Clinical Trial

Sep 11, 2017: A Paradigm Shift in Treating Osteoarthritis Pain

Aug 09, 2017: Paradigm Successfully Doses First Participant in Phase 2 Ross River Virus Clinical Trial

Jul 10, 2017: Paradigm to Commence Phase 2 Ross River Virus Clinical Trial

May 16, 2017: Paradigm’s preclinical hay fever trial: peer-reviewed and published in leading scientific journal

Mar 23, 2017: Paradigm Biopharmaceuticals Announces Final participant treated in Phase 2 hay fever trial

Mar 07, 2017: The Australian Company Testing a Breakthrough Treatment for Ross River

Nov 22, 2016: Paradigm Phase 2 Hay Fever Trialgets Approval from Swedish MPA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2018

Pipeline by Pfizer Inc, H1 2018

Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Dormant Projects, H1 2018

Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports